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Abstract Purpose: The SecondMultidisciplinary Forum: Parathyroid Hormone (PTH)
Use in Osteoporotic Patients at High Risk for Fractures (HRF) was con-
ducted to identify specific findings that would be helpful for defining high-
risk status and guiding the use of parathyroid hormone 1-84 (PTH1-84) as an
anabolic therapy in daily clinical practice. This article summarizes the con-
clusions from the meeting.
Materials and Methods: Based on three typical case records, and the final con-
clusions from the first Forum (held in 2010), several questions were posed re-
garding daily clinical practice definitions of HRF and use of PTH1-84, through a
series of 19 meetings throughout Spain. The main discussion topics and agreed
conclusions were collected by meeting coordinators and shared at a meeting held
in May 2011. After extensive discussions, which also included other organiza-
tional and educational matters, some newly agreed conclusions were reached.
Results: The consensus was that an HRF patient is usually thought of as
being elderly (aged >70 years), with a very low bone mass or a prevalent
fracture, and some other associated risk factors. High-risk groups who were
identified included patients with neurologic diseases, institutionalized in-
dividuals, and patients receiving long-term steroid therapy. PTH1-84 was
considered a safe and effective drug, having added value because of its an-
algesic effect and good level of patient adherence. Opportunities for improved
PTH1-84 use were identified, such as better patient selection and follow-up
based on localization and specialty. Some improvement opportunities were
also detected in organizational and educational areas.
Conclusion: The Forum identified differences between clinical recommendations
and daily clinical practice. Some elements, involving both organizational and
educational areas that could help to reduce such discrepancies, are described.
*A list of the Forum meeting coordinators can be found in the Acknowledgments section.
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Introduction
In the last 10–20 years, knowledge regarding
risk factors and diagnosis of osteoporosis, as well
as the various effective therapies that are avail-
able, has improved. Taking into account the
current deep global economic crisis, responsible
use of available limited resources is mandatory.
In such a context, identification of patients
with a significant fracture risk is an increasingly
important issue, with diverse approaches having
been used, based on a combination of several risk
factors, morphologic measures, genetic variants,
and other inputs.[1-9] While widely disseminated
tools to estimate the absolute risk for fractures
(e.g. the current FRAX tool), based on several
years’ hard work,[10-12] are an undoubtedly useful
approach that can be used in daily clinical care
where no expertise on osteoporosis is available, a
number of limitations remain.[3-5] Moreover, in
some countries, only patients with a high risk for
fractures according to FRAX are considered
for reimbursement for certain anti-osteoporotic
treatments.
Despite several clinical practice guidelines being
available for osteoporosis (the Spanish Society for
Bone Mineral Research [SEIOMM] guidelines[13]
being particularly important in Spain),[13-18] the
real use of such guidelines is notoriously low, and
their impact on clinical practice is sometimes
small.[19,20] Thus, a better understanding of physi-
cians’ perceptions and the determinants of real-life
clinical practice is required.
To develop this understanding, a project was
conducted [the Second Multidisciplinary Forum:
Parathyroid Hormone (PTH) Use in Osteoporotic
Patients at High Risk for Fractures (HRF)] to ex-
pand on the conclusions from the First Multi-
disciplinary Forum.[21] A strategy was implemented
to improve the understanding of factors determin-
ing a perceived high risk for osteoporotic fracture
and real-life clinical practices associated with the
use of anabolic drugs—specifically, parathyroid
hormone 1-84 (PTH1-84), which is indicated for
high-risk osteoporosis—among a large number of
physicians involved in osteoporosis therapy in
Spain, the country with the highest use of anabolic
therapy in Europe.[22] The project aimed to develop
consensus statements that could help guide clini-
cians in their decision-making processes. The first
Forum[20] reached some conclusions on major
osteoporosis risk factors and on the identification
of patients at the highest risk for fractures, who
could benefit from anabolic therapy. Based on
these conclusions, two main initial questions were
posed for the second Forum:
 What are the characteristics that result in a
specific patient being considered anHRF patient
in clinical practice, and how can this fact in-
fluence treatment selection?
 How is PTH1-84 used in HRF patients? What
is the patient profile? When and for how long
is PTH1-84 used to treat HRF?
A summary of the conclusions from the second
Forum is described here.
This article does not aim to be a systematic re-
view; rather, it aims to provide an account of the
discussions that took place at the Forum and
conclusions that were reached by physicians in
Spain.
Materials and Methods
The first phase of the second Forum was co-
ordinated by various local leaders and included
19 discussion platforms across Spain, involving
more than 300 participants. (The coordinators,
institutions, and locations of these Forum meet-
ings are listed in the Acknowledgments section.)
All groups used the general report on methods
and conclusions from the First Forum and three
typical clinical case presentations (table I) to aid
discussion on both key questions that were posed.
Conclusions were reached by consensus at each
meeting and were later shared at a general meet-
ing that was held in Madrid in late May 2011.
During this second phase, reports on the final
results from the debates among the initial groups
were presented by each meeting coordinator.
Final conclusions were reached by consensus.
Results
Taking into account the large number of meet-
ings and participants, including different specialists
with different perspectives on osteoporosis, the
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conclusions and reflections are obviously diverse.
They have been classified according to the follow-
ing items for summary and reporting purposes.
The High Risk for Fracture (HRF) Patient Profile
The HRF patient profile is obviously difficult
to define and characterize, as was previously
found at a preliminary meeting in 2010. However,
the following features have been identified as the
most relevant and/or distinctive (they were all
previously identified by the first Forum[20]):
 Elderly patients: older than 65 years or, as
concluded at most meetings, older than 70
years (older than 85 years was even suggested
by some groups).
 Prevalent osteoporotic fracture: according to a
significant number of meetings, patients with a
history of two prevalent osteoporotic fractures
(or a single hip fracture) are at particularly high
risk. Patients with a single fracture are consid-
ered to be potentially high risk if they have
additional major risk factors (e.g. frequent falls
[more than 3 per year]), are elderly, or have a
very low bone mass, among other factors.
 Very low bone mass (T score lower than -3
or -3.5).
 Presence of three or more major risk factors.
 Secondary osteoporosis or primary osteoporosis
associated with disease that can result in HRF
due to various causes:
* Neurologic diseases, such as cerebrovascular
events, Parkinson’s disease, spinal cord
syndromes, and other disorders that can
result in an increased frequency of falls.
* Rheumatologic or other diseases with a risk
resulting from the disease itself, and an
added risk due to deleterious effects of
therapy (for instance, long-term steroid
treatment in rheumatoid arthritis patients).
* Institutionalized patients: besides their old
age, they usually have vitamin D deficiency,
sarcopenia with a low protein intake, a
tendency to fall, and several co-morbidities.
Both the diseases themselves and their
treatment result in HRF.
According to participants at the meetings,
when several risk factors are present, the overall
risk is substantially increased (for instance, a
high-risk patient might be one who is 70 years old
with a prevalent vertebral fracture and low fem-
oral bone mass).
Regarding treatment selection, some groups re-
commended using aminobisphosphonates (alendr-
onate, risedronate, or zoledronate) or strontium
ranelate in patients younger than 65 years, with
anabolic therapy being a treatment of choice for
patients older than 65 years. It must be noted that
denosumab, which is now approved for use in this
indication, was not available at the time of these
discussions.
Use of Parathyroid Hormone 1-84 (PTH1-84) in
Clinical Practice
Anumber of PTHs are available for clinical use.
At the Forummeetings, the practical use of PTH1-
84, a recombinant human PTH, in the treatment of
osteoporosis was discussed. As an anabolic ther-
apy, PTH1-84 has shown anti-fracture efficacy in
HRF patients, i.e. patients with a prevalent verte-
bral fracture or very low bone mass.[23] The
following conclusions were reached by Forum
participants:
Table I. Clinical case presentations used at the Forum meetings
Case no. Characteristic
Case 1 Postmenopausal woman
Low bone mineral density (-3)
Low body mass index
Previous Colles’ fracture
Bisphosphonate and calcium supplement therapy
Two vertebral fractures, thoracic-lumbar pain
Case 2 Postmenopausal woman
Low bone mineral density
Family history of hip fracture (in her mother)
Long-term rheumatoid arthritis; corticosteroid therapy
Limited motility, poor quality of life
Case 3 Postmenopausal woman
Low bone mineral density
Family history of fracture
Long-term bisphosphonate therapy
Previous osteoporotic fracture
Current subtrochanteric femur fracture
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 Anabolic treatment with PTH1-84 is effective,
safe, and well tolerated, while adherence to
treatment is surprisingly good, considering
that it is administered subcutaneously on a
daily basis. It has an analgesic effect and
results in a substantial improvement in quality
of life. According to the perceptions of most
participants, it has a more rapid effect than
anti-catabolic agents.
 The most relevant patients to receive anabolic
therapy with PTH1-84 are:
* Patients recently diagnosed with HRF, i.e. a
risk higher than that warranting standard
therapy, as mentioned in the previous section.
* Patients receiving anti-catabolic agents (bis-
phosphonates, selective estrogen-receptor
modulators [SERMs], calcitonin) or dual-
action drugs (strontium ranelate) and
showing poor or no densitometric response
(i.e. significant loss of bone mineral density
when measured with the same device, and
higher than its variability coefficient).
* Patients receiving anti-catabolic or dual-
action drugs who present with an osteopor-
otic fracture, if such a finding seems to be a
reasonable indication of therapeutic failure
or alters the patient risk profile (for instance,
a hip fracture in a patient receiving a drug
with no demonstrated efficacy for prevention
of such a fracture type [such as some
bisphosphonates, SERMs, or calcitonin], or
a fracture that should have been prevented
with a therapy that has proven efficacy after
a reasonable therapy period).
* Patients treated for more than 5–10 years
with strong bisphosphonates and showing
persistent HRF in spite of such therapy, if a
concern exists regarding the potential ac-
cumulative effect of such drugs.
* Patients with a significant fracture risk and
one of the rare clinical conditions asso-
ciated with use of strong anti-catabolic
drugs, such as jaw osteonecrosis or
atypical femur fractures. Although a clear-
cut cause has not been established, such
conditions have been related to an excessive
anti-resorptive effect. Thus, use of anabolic
agents seems particularly attractive in such
cases. Available data on their efficacy are,
however, scarce or non-existent.
 Treatment should be started after verification
of adequate calcium and vitamin D intake.
Anabolic agents, such as PTH1-84, result in
new osteoid formation, requiring adequate
vitamin D levels to achieve enough minerali-
zation; but some data suggest that most
osteoporotic patients are deficient in vitamin
D. If vitamin D cannot be assessed, initiation
of average vitamin D3 or 25(OH) vitamin D
doses seems a reasonable recommendation
before therapy is started. Also, dose equiv-
alents of 800–1000 IU/day should be used
during therapy, and increased dietary intake
of calcium (up to 1000 or 1200mg/day) or use
of food supplements is recommended.
 Anabolic therapy efficacy has been proven in
18- to 24-month clinical trials; shorter-term
use does not guarantee full efficacy. Increased
blood or urine calcium levels do not usually
cause any clinical manifestations, nor do
they require treatment regimen changes. If
necessary, calcium and vitamin D supplements
should be discontinued and, if this is not
sufficient, PTH1-84 should be used every other
day.[23]
 Bone mass gains achieved with PTH1-84
anabolic therapy must be consolidated by later
administration of anti-catabolic agents. Most
available data support later use of amino-
bisphosphonates, but denosumab may be a
good alternative option, based on its anti-
catabolic strength and reversible effect with no
deposit in bone tissue.
 Anabolic agents are currently being used ‘‘off
label’’ for some disorders that are not included
in their Summaries of Product Characteristics,
such as fracture consolidation delay, pseu-
doarthrosis, after prosthesis implants or total
joint replacement, aseptic prosthesis loosen-
ing, Su¨deck’s algodystrophy, acute vertebral
fractures with poor pain control, or peri-
prosthetic fracture. Despite unproven efficacy
in such conditions, therapy is often adminis-
tered for some months (until clinical resolu-
tion of underlying causes), and sometimes for
up to 24 months.
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Current Needs and Opportunities for
Improvement in Organizational Issues
Some recommendations were provided re-
garding the need for improvement in organiza-
tional issues, including the following:
 The cost implications of therapy are recognized
in a finite-resource scenario, particularly in the
present context of a deep economic crisis.
Taking into account that available treatments
for osteoporosis have proved to be efficient in
reducing fracture incidence and complications,
available resources should be used in the most
efficient way. Thus, such therapies should be used
in patients with a significant fracture risk and
during life periods when such a risk is really
apparent. Use of strong anti-osteoporotic treat-
ments in low-risk patients is unreasonable, where-
as therapy denial or failure to recognize disease
occurrence in patients at risk is irresponsible.
 A multidisciplinary team approach is recom-
mended for osteoporotic patients; such teams
would be particularly effective when treating
HRF patients.
* Current interest in osteoporosis is highly
variable across medical specialties and geogra-
phic areas. No general rule can be established
as to which medical specialists are most
suitable for the care of osteoporotic patients.
* One situation that needs to be improved is
patient care after admission with an osteopor-
otic fracture; a large number of patients do not
receive the correct diagnosis and therapy after
initial treatment of the acute event. Such
patients show high bone fragility and would
mostly benefit from appropriatemanagement.
* At least some members of medical depart-
ments currently treating patients with prev-
alent fractures or HRF patients (orthopedic
surgery, rehabilitation, geriatrics, and
others) should be involved in protocol
development for osteoporotic patient care.
* Primary care physicians should be involved
in the diagnosis, treatment, and follow-up
of patients initially treated by other special-
ists (such as orthopedic surgeons). Agreed
patient selection processes should be
established. There is an obvious need for
better information flow across care levels
through clinical reports and regular meet-
ings or dedicated multilevel teams.
 Densitometer availability is highly variable.
Although densitometry is not mandatory for
initial risk assessment, it can be needed in some
moderate-risk cases; bonemassmay be a critical
factor for therapy selection. Thus, public and
private health systems should provide such
diagnostic tests.
 Clinical inertia is currently limiting best therapy
selection, particularly in HRF patients. The
patient risk profile should be regularly re-
assessed, and the efficacy/safety index for a
prescribed treatment should be evaluated in
order to achieve the best results.
Current Needs and Opportunities for
Improvement in Continuing Medical
Education
Continuing medical education needs were also
discussed at the meetings. Patients with osteopor-
osis are currently treated by different medical
specialties (primary care physicians, orthopedic
surgeons, rheumatologists, rehabilitation special-
ists, internists, endocrinologists, geriatricians, gy-
necologists, and others) with highly heterogeneous
expertise and involvement in osteoporosis man-
agement. High-quality protocols and education
programs addressing practical issues associated
with managing patients with osteoporosis should
be developed. This is particularly true in HRF
patients (such as those receiving secondary pre-
vention measures). A general perception of high
therapy heterogeneity, not fully supported by pa-
tient profile differences, was identified.
Quality of care also seems to show great dif-
ferences, such as those involving:
 Basic laboratory testing for secondary
osteoporosis screening.
 Overall fracture risk assessment.
 Appropriate therapy selection for patients at
risk, particularly those receiving secondary
prevention measures after an osteoporotic
fracture. Clinical practice guidelines based on
systematic literature reviews are very useful.
Among them, the SEIOMM guidelines,[13]
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which will be updated soon, are probably the
most widely accepted guidelines in Spain.
* Regarding PTH1-84 anabolic therapy, some
specific needswere recognized. Thesewere the
need for regular blood calcium monitoring, a
better understanding of its effect (such as
increased levels of remodeling markers [in-
cluding total alkaline phosphatase], poten-
tial analgesic effects, improved quality-of-
life scores), and improved knowledge of
contraindications to its use in patients with
a previous cancer history.
* Changes in modifiable risk factors for osteo-
porosis (smoking habits, excessive alcohol in-
take, vitaminDdeficiency, low calcium intake,
and sedentary lifestyle); prevention of falls
(correction of visual deficiencies and identifi-
cation of potential risk behaviors or objects).
* Adequate intake and persistent use of
prescribed treatment: prescribing clinicians
should provide their patients with appropri-
ate information about how to take drugs and
the importance of sustained treatment to
achieve full efficacy. General practitioners
and family physicians should commonly use
effective strategies, such as the Batalla or
Morinsky-Green tests,[24] to detect lack of
adherence and/or persistence.
* Follow-up needs: a clear-cut difference should
be recognized between specific bone metab-
olism units or services and the usual clinical
practice context, which does not require use of
densitometry or bone remodeling markers for
appropriately selected patients.
* Use of therapy for an adequate period in
order to achieve its full efficacy: 24 months
for anabolic treatments, or at least 3–5 years
for anti-catabolic and mixed treatments.
* Re-assessment or referral of poorly re-
sponding patients and patients showing
therapy failure to experienced centers.
Consensus Conclusions
 Patients with a clear-cut prevalent osteopor-
otic fracture are at HRF (secondary preven-
tion). The risk is higher in patients withmultiple
fractures. Definition of a high-risk profile, how-
ever, is variable across medical specialties
because of different clinical risk factors, such
as advanced age, long-term steroid use, or
neurologic co-morbidities.
 Treatment with PTH1-84 for 18–24 months is
safe and effective. It should be used as follows:
* First-line therapy for HRF patients.
* Second-line therapy for patients with intoler-
ance of anti-catabolic or mixed therapy, or
therapy failure (e.g. fracture occurrence).
* Suspected potential complications due to
long-term use of anti-catabolic drugs.
 Individually tailored therapy should be initiated
after adequate screening for causes of secondary
osteoporosis and correction of modifiable risk
factors. Adequate calcium and vitaminD intake
should also be ensured.
 Specific strategies are needed to improve
patient adherence and persistence, in order to
achieve a good outcome.
Discussion
Relevant medical information about the causes
of osteoporosis, the disease course, and therapy
has dramatically increased in recent years. Keep-
ing up with such developments is virtually impos-
sible for non-specialists. Thus, carefully evaluated
and prioritized clinical practice guidelines, based
on systematic review of the available relevant
literature and the best international standards,
are clearly needed.[25-27] There are multiple clin-
ical practice guidelines on osteoporosis;[13-18] in
Spain, the SEIOMM guidelines[13] are those most
widely accepted.
Such guidelines are, however, scarcely used in
daily clinical practice,[19,20] and the situation has not
significantly improved in the last few decades.[28]
Therefore, better knowledge of characteristics and
determinants of real-life clinical practice is clearly
needed, to help identify organizational and educa-
tional needs in order to minimize the gap between
what should be done and what is currently being
done in real-life clinical practice.
This is particularly relevant when trying to
identify patients with the highest risk for frac-
tures and fracture complications, such as those
with functional impairment, loss of health-related
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quality of life, or loss of life years. Taking into
account our current need to match available health-
care resources to those patients who are likely to
obtain the greatest benefit, an improved under-
standing concerning the real-life use of one of the
most powerful therapies in the current therapeutic
armamentarium for osteoporosis is important.
Some limitations are clearly evident in our work,
including the lack of a systematic review of the
available evidence and the lack of a formal method
for discussions. However, our identification of
significant differences between recommendations
based on systematic reviews developed by scientific
societies or various organizations and real clinical
practice reflects current perceptions from a large
number of physicians involved in real-life osteopor-
osis care in Spain.
The Forum identified patient selection strategies,
treatment rationalization and multidisciplinary
team access as focus areas and recommended that
changes be made. These could be implemented
with minimal cost because they relate to physi-
cian behavior and patient management rather
than changes to the healthcare infrastructure.
The suggestions to improve continuing education
programs would require more investment but,
given that among Spanish individuals, the ten-
year risk for major fracture is 5.5% for women
and 2.8% for men,[29] the healthcare demands,
functional impairment, and quality-of-life con-
sequences represent a considerable burden.
Therefore, there is a considerably sized patient
population that would benefit from an improve-
ment, and a moderate investment to improve
their management would be worthwhile.
Patient selection strategies and therapy selection
improvements have been suggested and, most im-
portantly, needs for organizational improvements
(such as multidisciplinary team access), and edu-
cational requirements that can help design new
strategies with an impact on osteoporosis care im-
provement, have been highlighted.
Acknowledgments
The author would like to thankNycomed/Takeda for their
assistance in the preparation of the various meetings and, es-
pecially, the more than 300 participants at these meetings.
This study was sponsored by Nycomed/Takeda. Medical
writing services were provided by Javier Mas of Edmonds SL
and funded by Nycomed/Takeda. Native English editing of
the manuscript was provided by Andrea Bothwell of inScience
Communications, Springer Healthcare, with funding from
Nycomed/Takeda. The author, Dr. Esteban Jo´dar Gimeno,
meets the criteria for authorship as recommended by the In-
ternational Committee of Medical Journal Editors (ICMJE),
was fully responsible for all content and editorial decisions,
and was involved at all stages of manuscript development. The
author declares no conflicts of interest that are directly rele-
vant to the contents of this study.
Coordinators, Institutions, and Locations of the Forum
Meetings: FranciscoMartinez Martı´nez, Hospital Virgen de la
Arrixaca, Murcia; Javier Aguilar del Rey, Hospital Clinico
Malaga, Ma´laga; Antonio Garcia Sa´nchez, Hospital San Ce-
cilio, Granada; Vicente Climent, Hospital Xativa, Valencia;
Chesus Beltran Audera, Hospital Miguel Servet, Zaragoza;
Xoan Miguens, Hospital Monforte de Lemos, Leo´n; Ignacio
Gonzalez-Busto Mujica, Hospital Central Asturias, Asturias;
Santiago Benito Urbina, Hospital San Milla´n San Pedro,
Logron˜o; Felix Cebeiro, Hospital Basurto, Bilbao; Ernesto
Candau, Hospital Rio Hortega, Valladolid; In˜igo Hernandez,
Complejo Hospitalario Universitario de Vigo, Vigo; Emilio
Garcı´a Atanes, Hospital Barbanza, Oleiros; Bibiana Villa-
mayor Blanco, Complexo Hospitalario Universitario de San-
tiago, Santiago; Teresa Torralba, Hospital Cruces, Bilbao;
Jose Augusto Lorenzo Rivero, Hospital Dr. Negrin, Gran
Canaria; Rosa Gonzalez Crespo, Hospital 12 de Octubre,
Madrid; Juan Sanchez Burso´n, Hospital Valme, Sevilla;
Antonio Sanchez Granados, Hospital Virgen del Rocio, Sev-
illa;Manuel Roman Torres, Hospital Reina Sofı´a, Cordoba.
References
1. Aubry-Rozier B, Lamy O. Fracture risk, new treatments:
how does the management of the osteoporosis of elderly
change? Rev Med Suisse 2010 Mar 17; 6 (240): 569-70,
572-4
2. SteinerML, Fernandes CE, Strufaldi R, et al. Application of
Osteorisk to postmenopausal patients with osteoporosis.
Sao Paulo Med J 2010 Jan; 128 (1): 24-9
3. Tremollieres FA, Pouilles JM, Drewniak N, et al. Fracture
risk prediction using BMD and clinical risk factors in
early postmenopausal women: sensitivity of the WHO
FRAX tool. J Bone Miner Res 2010 May; 25 (5): 1002-9
4. Azagra R, Roca G, Encabo G, et al. Prediction of absolute
risk of fragility fracture at 10 years in a Spanish population:
validation of the WHO FRAX tool in Spain. BMC Mus-
culoskelet Disord 2011 Jan 28; 12: 30
5. Lippuner K, Johansson H, Kanis JA, et al. FRAX assess-
ment of osteoporotic fracture probability in Switzerland.
Osteoporos Int 2010 Mar; 21 (3): 381-9
6. LaCroix AZ, Beck TJ, Cauley JA, et al. Hip structural ge-
ometry and incidence of hip fracture in postmenopausal
women: what does it add to conventional bone mineral
density? Osteoporos Int 2010 Jun; 21 (6): 919-29
7. Cheung CL, Sham PC, Chan V, et al. Identification
of LTBP2 on chromosome 14q as a novel candidate
gene for bone mineral density variation and fracture risk
Identifying Patients at High Risk for Fractures 205
Adis ª 2012 Jo´dar Gimeno, publisher and licensee Springer International Publishing AG. Drugs R D 2012; 12 (4)
association. J Clin Endocrinol Metab 2008 Nov; 93 (11):
4448-55
8. Blaizot S, Delmas PD, Marchand F, et al. Risk factors for
peripheral fractures vary by age in older men—the pro-
spective MINOS study. Osteoporos Int 2011 Jun; 22 (6):
1755-64
9. Lih A, Nandapalan H, Kim M, et al. Targeted intervention
reduces refracture rates in patients with incident non-
vertebral osteoporotic fractures: a 4-year prospective con-
trolled study. Osteoporos Int 2011 Mar; 22 (3): 849-58
10. Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of
osteoporotic fractures according to BMD and diagnostic
thresholds. Osteoporos Int 2001 Dec; 12 (12): 989-95
11. Kanis JA, Johnell O, De Laet C, et al. International varia-
tions in hip fracture probabilities: implications for risk as-
sessment. J Bone Miner Res 2002 Jul; 17 (7): 1237-44
12. De Laet C, Oden A, Johansson H, et al. The impact of the
use of multiple risk indicators for fracture on case-finding
strategies: a mathematical approach. Osteoporos Int 2005
Mar; 16 (3): 313-8
13. Gonza´lez Macı´as J, Guan˜abens Gay N, Go´mez Alonso C, et
al. Guı´as de pra´ctica clı´nica en la osteoporosis pos-
menopa´usica, glucocorticoidea y del varo´n. Sociedad Es-
pan˜ola De Investigacio´n O´sea Y Del Metabolismo Miner-
al. Rev Clin Esp 2008 May; 208 (Suppl. 1): 1-24
14. Watts NB, Bilezikian JP, Camacho PM, et al. American
Association of Clinical Endocrinologists medical guide-
lines for clinical practice for the diagnosis and treatment of
postmenopausal osteoporosis: executive summary of
recommendations. Endocr Pract 2010 Nov-Dec; 16 (6):
1016-9
15. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical
practice guidelines for the diagnosis and management of
osteoporosis in Canada: summary. CMAJ 2010 Nov 23;
182 (17): 1864-73
16. Compston J, Cooper A, Cooper C, et al. Guidelines for the
diagnosis and management of osteoporosis in postmeno-
pausal women and men from the age of 50 years in the UK.
Maturitas 2009 Feb 20; 62 (2): 105-8
17. Kanis JA, Burlet N, Cooper C, et al. European guidance for
the diagnosis and management of osteoporosis in
postmenopausal women. Osteoporos Int 2008 Apr; 19 (4):
399-428
18. Kanis JA, Torgerson D, Cooper C. Comparison of the
European and USA practice guidelines for osteoporosis.
Trends Endocrinol Metab 2000 Jan-Feb; 11 (1): 28-32
19. Vos E. Osteoporosis guidelines miss big picture. CMAJ 2011
Apr 5; 183 (6): 695
20. Crabtree NJ, Bebbington NA, Chapman DM, et al. Impact
of UK national guidelines based on FRAX—comparison
with current clinical practice. Clin Endocrinol (Oxf) 2010
Oct; 73 (4): 452-6
21. Jo´dar Gimeno E. Conclusiones consensuadas del I Foro
Multidisciplinar en el Manejo del Paciente con Alto Riesgo
de Fractura (ARF) Osteoporo´tica. Rev Osteoporos Metab




22. Hosking D, Alonso CG, Brandi ML. Management of
osteoporosis with PTH: treatment and prescription
patterns in Europe. Curr Med Res Opin 2009 Jan; 25 (1):
263-70
23. Jo´dar-Gimeno E. Full length parathyroid hormone (1-84) in
the treatment of osteoporosis in postmenopausal women.
Clin Interv Aging 2007; 2 (1): 163-74
24. Gil VF, Belda J, Munoz C, et al. Validity of four indirect
methods which evaluate therapeutic compliance for arterial
hypertension. Rev Clin Esp 1993 Nov; 193 (7): 363-7
25. Appraisal of Guidelines, Research, and Evaluation in
Europe (AGREE) Collaborative Group. Guideline devel-
opment in Europe: an international comparison. Int J
Technol Assess Health Care 2000 Autumn; 16 (4): 1039-49
26. AGREE Collaboration. Development and validation of an
international appraisal instrument for assessing the quality
of clinical practice guidelines: the AGREE project. Qual
Saf Health Care 2003 Feb; 12 (1): 18-23
27. Burgers JS, Cluzeau FA, Hanna SE, et al. Characteristics of
high-quality guidelines: evaluation of 86 clinical guidelines
developed in ten European countries and Canada. Int J
Technol Assess Health Care 2003 Winter; 19 (1): 148-57
28. Cabana MD, Rand CS, Powe NR, et al. Why don’t physi-
cians follow clinical practice guidelines? A framework for
improvement. JAMA 1999 Oct 20; 282 (15): 1458-65
29. Sanfe´lix-Genove´s J, Sanfe´lix-Gimeno G, Peiro´ S, et al.
Prevalence of osteoporotic fracture risk factors and anti-
osteoporotic treatments in the Valencia region, Spain. The
baseline characteristics of the ESOSVAL cohort. Osteo-
poros Int. Epub 2012 May 23
Correspondence: Dr. Esteban Jo´dar Gimeno, Servicio de En-
docrinologı´a y Nutricio´n Clı´nica, Hospital Universitario




Adis ª 2012 Jo´dar Gimeno, publisher and licensee Springer International Publishing AG. Drugs R D 2012; 12 (4)
